KAT6A Syndrome

KAT6A syndrome is a rare, autosomal-dominant neurodevelopmental disorder caused by harmful (pathogenic) changes in the KAT6A gene, which encodes a histone acetyltransferase that helps switch other genes on and off during development. Most children have global developmental delay, marked speech and language delay, intellectual disability of variable degree, characteristic facial features, feeding problems (including reflux and constipation), hypotonia in infancy that may evolve, and sometimes eye misalignment (strabismus), sleep difficulties, and congenital anomalies. There is wide variability; some children walk and talk late but do well in supportive programs, while others need ongoing help with mobility, communication, and medical issues. At present there is no cure; early, coordinated therapies and targeted treatments for symptoms offer the best outcomes. PMC+3PMC+3PMC+3

KAT6A syndrome is a rare genetic condition that affects how a child grows, learns, and how many organs form and work. It happens when one copy of the KAT6A gene has a harmful change (mutation). The KAT6A gene makes a protein that adds acetyl groups to histone proteins. This “histone acetylation” turns on sets of genes that guide brain development, muscle tone, face shape, heart development, blood formation, and other body systems. When KAT6A does not work as it should, children commonly have global developmental delay, speech delay or few words, low muscle tone (hypotonia), feeding and swallowing problems, and distinct facial features. Some children also have heart defects, vision problems, gastrointestinal issues, sleep problems, and sometimes microcephaly. Most mutations are new (de novo) in the child, though rare families show inherited variants with variable severity. PMC+4National Organization for Rare Disorders+4Orpha+4

Scientifically, KAT6A (also called MOZ or MYST3) is part of a histone-acetyltransferase complex that helps control which genes are active during early development. Disruptions change gene programs in the brain, heart, blood, and other tissues, explaining the multi-system features seen in this syndrome. PubMed+2ScienceDirect+2

Other names

KAT6A syndrome is also known as:

• Arboleda-Tham syndrome (ARTHS)

• Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome

• Autosomal dominant mental retardation 32 (MRD32; MIM #616268)
  These names all refer to the same disorder caused by pathogenic variants in KAT6A. rarediseases.info.nih.gov+2National Organization for Rare Disorders+2

Types

Doctors usually classify KAT6A syndrome by variant class and clinical pattern rather than by separate disease “subtypes”:

1. Protein-truncating variants (nonsense, frameshift, some splice) — often linked to more typical features and, in some studies, more marked cognitive impact. PMC+1

2. Missense variants — can be milder or variable; a few families have inherited missense changes. PMC+1

3. Variant location effects (genotype–phenotype correlation) — “late-truncating” variants may correlate with specific features (e.g., more feeding and GI issues) in cohort analyses. PMC

4. Mosaic or inherited cases — uncommon but documented; phenotype can vary among relatives with the same variant. PubMed

Causes

Because KAT6A syndrome is genetic, “causes” focus on the kinds of DNA changes and biological mechanisms that disrupt KAT6A’s function:

1. De novo truncating mutations (new in the child) leading to loss of function. PMC+1

2. De novo missense mutations altering key protein domains and enzyme activity. PMC

3. Frameshift variants producing premature stop codons and unstable mRNA/protein. PMC

4. Nonsense variants causing early stop and haploinsufficiency. PMC

5. Canonical splice-site mutations disrupting RNA splicing and protein structure. PMC

6. Non-canonical splice variants with partial mis-splicing and variable impact. PMC

7. Missense variants in the HAT (acetyltransferase) domain perturbing histone acetylation. ScienceDirect

8. Missense variants in other conserved domains affecting protein–protein interactions in the KAT6 complex. ScienceDirect

9. Late-truncating variants associated with specific clinical clusters in cohort studies. PMC

10. Inherited missense variants (rare) causing variable expression in families. PubMed

11. Parental mosaicism for truncating variants (rare) passing the variant to a child. PubMed

12. Chromosomal rearrangements involving KAT6A (very rare) disrupting gene integrity. PubMed

13. Regulatory region variants (hypothesized/rare) altering KAT6A expression. (Inferred from regulatory roles of KAT6A; reported evidence in related HAT genes suggests plausibility.) ScienceDirect

14. Epigenetic dysregulation downstream of KAT6A leading to broad gene-expression changes. PMC

15. Perturbed hematopoietic gene programs (KAT6A critical in blood development) explaining occasional blood findings. PubMed

16. Neurodevelopmental pathway disruption during cortical development from reduced histone H3 acetylation (e.g., H3K9/K23). ScienceDirect

17. Cardiac developmental gene mis-regulation causing congenital heart anomalies in a subset. PMC

18. Oromotor and cranial nerve program disruption contributing to feeding/speech difficulties. BioMed Central

19. Vision pathway involvement causing strabismus/ptosis in some individuals. BioMed Central

20. Multi-system gene-regulation defects across KAT6A target networks, explaining variability across patients. MDPI

Common symptoms and clinical features

1. Global developmental delay and intellectual disability — delays in milestones (sitting, walking) and learning; severity varies. National Organization for Rare Disorders+1

2. Speech and language delay — many children speak late, have few words, or need alternative communication methods. National Organization for Rare Disorders

3. Hypotonia (low muscle tone) — “floppy” feel in infancy; may persist and affect coordination and feeding. rarediseases.info.nih.gov

4. Feeding and swallowing problems — poor suck, reflux, choking, or aspiration; some need thickened feeds or tube support. PMC

5. Distinct facial features — commonly a broad nasal tip and thin, tented upper lip; features can be subtle. rarediseases.info.nih.gov

6. Congenital heart defects — such as septal defects; require cardiology evaluation and sometimes surgery. National Organization for Rare Disorders

7. Microcephaly in some children — head size smaller than expected; brain MRI may be normal or show mild changes. BioMed Central

8. Vision issues — strabismus (eye misalignment), ptosis (droopy eyelids), or refractive errors needing glasses or surgery. BioMed Central

9. Gastrointestinal problems — reflux, constipation, or motility issues; often part of the early care plan. PMC

10. Sleep disturbance — difficulties falling or staying asleep; may relate to reflux, tone, or neurodevelopment. BioMed Central

11. Frequent infections in some — likely multifactorial; routine vaccines and monitoring are important. rarediseases.info.nih.gov

12. Behavioral profile — studies suggest relatively good social drive and strengths in behavior regulation despite language challenges. PubMed

13. Motor coordination challenges — low tone and delayed motor planning can affect stamina and balance. National Organization for Rare Disorders

14. Oromotor dysfunction — drooling, articulation difficulty, oral hypotonia impacting speech and feeding skills. BioMed Central

15. Variable severity — even within the same family; some walk and talk with supports, others need more intensive help. PubMed

Diagnostic tests

A) Physical exam (bedside assessment)

1. General pediatric exam — assesses growth, head size, tone, reflexes, and dysmorphic features; guides targeted testing. rarediseases.info.nih.gov

2. Neurologic exam — documents hypotonia, motor coordination, and developmental level to shape therapies. National Organization for Rare Disorders

3. Cardiac exam — murmurs or signs of heart defects prompt echocardiography and cardiology referral. National Organization for Rare Disorders

4. Ophthalmologic screening exam — catches strabismus/ptosis early for vision protection. BioMed Central

5. Growth and nutrition assessment — weight gain, feeding tolerance, and reflux signs guide nutrition support. PMC

B) Manual / functional tests (standardized developmental and therapy tools)

6. Developmental assessment scales (e.g., Bayley Scales) to profile cognitive, language, and motor skills and track progress. National Organization for Rare Disorders

7. Speech–language evaluation — measures expressive and receptive language; supports AAC (augmentative and alternative communication) decisions. BioMed Central

8. Feeding and swallowing evaluation by speech/feeding therapists for oromotor skills and aspiration risk. PMC

9. Occupational therapy assessment — examines fine motor skills, coordination, and daily living skills; plans interventions. National Organization for Rare Disorders

10. Physical therapy assessment — evaluates posture, tone, and gait to set strengthening and mobility plans. National Organization for Rare Disorders

C) Laboratory and pathological tests

11. Chromosomal microarray (CMA) — first-line genomic screen to detect rare deletions/duplications affecting KAT6A or nearby regions. (Often normal; still important early step.) National Organization for Rare Disorders

12. Clinical exome sequencing (trio preferred) — the main test to detect KAT6A variants; confirms diagnosis. PMC

13. Targeted KAT6A sequencing / Sanger confirmation — validates a suspected variant and checks parental samples for inheritance or mosaicism. BioMed Central

14. RNA studies (if available) — clarify impact of splice variants when DNA results are uncertain. PMC

15. Baseline blood tests (CBC, iron, thyroid as indicated) — screen common comorbidities and rare reports (e.g., a case with marrow failure). PubMed

D) Electrodiagnostic tests

16. EEG — performed if there are spells concerning for seizures or unusual staring episodes. (Seizures are not universal but can occur in neurodevelopmental syndromes.) National Organization for Rare Disorders

17. Swallowing physiology study (videofluoroscopy) — though imaging-based, therapists use it functionally to assess aspiration risk; helps plan safe feeding. PMC

18. EMG/nerve studies — rarely, to evaluate unexplained hypotonia/weakness when the clinical picture is atypical. National Organization for Rare Disorders

E) Imaging tests

19. Echocardiogram — essential if exam or history suggests a congenital heart defect. National Organization for Rare Disorders

20. Brain MRI — done for significant microcephaly, tone issues, or developmental concerns; may be normal or show nonspecific changes. BioMed Central

Non-pharmacological treatments (therapies & other supports)

Below are practical, family-centered interventions. None “cure” KAT6A, but together they build skills, reduce complications, and improve quality of life.

1. Early intervention program
   Enroll as soon as KAT6A is suspected. Coordinated infant-toddler services (PT/OT/speech/feeding, educator visits) build motor control, communication, and daily-living skills during the brain’s most plastic years. Families learn home-program strategies and how to access adaptive equipment and school supports. Early, steady input is linked with better functional outcomes across rare neurodevelopmental disorders, including KAT6A. National Organization for Rare Disorders+1

2. Speech-language therapy with AAC
   Speech delay is a core feature. Start speech therapy early and introduce augmentative and alternative communication (AAC) (picture boards, tablets, or sign language) so the child can communicate now—not just later. AAC never blocks speech; it often accelerates language learning and reduces frustration. KAT6A cohorts report substantial expressive-language delay, making AAC a high-value support. PMC+1

3. Physical therapy (PT)
   PT targets hypotonia, delayed sitting/standing/walking, and later balance or coordination issues. Programs use strengthening, balance training, gait practice, and orthoses when needed. The aim is safe mobility, endurance for play and school, and prevention of contractures. PT is standard in KAT6A care plans described in case series and family guidance. PMC+1

4. Occupational therapy (OT) & fine-motor training
   OT builds hand function, self-care (feeding, dressing, toileting), and sensory processing. Therapists adapt utensils, seating, and writing tools; they also train caregivers in daily-routine practice at home and school. This improves independence and reduces caregiver burden. National Organization for Rare Disorders

5. Feeding therapy & safe-swallow management
   Feeding teams (SLP/OT + GI) evaluate swallow safety, endurance, reflux, and oral-motor skills. Plans include texture modification, pacing, positioning, and, when needed, temporary tube feeding. These steps reduce aspiration risk and improve growth—important in KAT6A where feeding difficulties are common. National Organization for Rare Disorders+1

6. Reflux positioning & sleep hygiene
   Upright, calm post-feed routines; head-of-bed considerations; and structured bedtimes can lessen reflux discomfort and improve sleep. For persistent symptoms, clinicians follow pediatric GERD guidelines to decide on testing or medicines. Good sleep supports learning and behavior. NASPGHAN

7. Constipation routines
   Daily fluids, fiber-rich foods as tolerated, scheduled toileting, and movement are first-line. If inadequate, pediatricians may add evidence-based laxatives (see “Drugs”). Consistent routines prevent pain, stool withholding, and feeding aversion. PMC

8. Vision care & strabismus management
   Regular pediatric ophthalmology visits catch refractive errors, amblyopia, and strabismus early. Glasses, patching, or (if needed) surgery protect vision and depth perception—crucial for motor development. AAO+1

9. Hearing screening & supports
   Hearing issues—conductive or sensorineural—may worsen speech delay. Early detection and amplification (hearing aids/ossicular fixes) allow better speech therapy progress. Routine audiology is recommended in developmental syndromes with language delay. National Organization for Rare Disorders

10. Behavioral & educational therapy
    Individualized education programs (IEPs), special-education supports, and behavior therapy teach communication, adaptive behavior, and classroom skills. Parent coaching aligns home and school strategies for steadier gains. National Organization for Rare Disorders

11. Social-skills coaching & play-based groups
    Structured peer interactions, visual schedules, and role-play help pragmatic language and reduce anxiety in new settings. This is common in neurodevelopmental programs and beneficial in KAT6A’s social-communication profile. National Organization for Rare Disorders

12. Orthotics & mobility aids
    Ankle-foot orthoses, standers, walkers, or lightweight wheelchairs may be used temporarily or long-term to promote alignment, endurance, and independent movement. Decisions are individualized by PT/orthopedics. National Organization for Rare Disorders

13. Feeding-tube (short- or long-term) support education
    If oral intake does not meet growth or hydration needs, temporary nasogastric tubes or gastrostomy (G-tubes) can be life-improving solutions. Teams teach safe care, weaning plans, and blended-diet options under dietitian guidance. NASPGHAN

14. Sleep-disordered breathing evaluation
    Snoring, restless sleep, or daytime effects should prompt assessment for obstructive sleep apnea (OSA); adenotonsillectomy is first-line when indicated, with CPAP for residual OSA. Better sleep boosts daytime learning and mood. AAP Publications+1

15. Care coordination & genetics counseling
    A medical home coordinates therapies, monitors growth, and screens for associated issues. Genetics teams explain inheritance, recurrence risk, and options for future pregnancies. This reduces uncertainty and supports family planning. National Organization for Rare Disorders

16. Parent support & condition-specific communities
    Peer networks (e.g., KAT6A foundations) share practical strategies for schooling, feeding, medical visits, and funding equipment—improving caregiver resilience. Kat6A

17. Dietitian-guided nutrition
    Dietitians tailor calories, textures, and micronutrients (iron, vitamin D) to growth and feeding skills; they also help with constipation and reflux diet tactics consistent with pediatric GERD guidance. PMC

18. Dental & oral-motor care
    Regular dental visits and desensitization routines prevent cavities in children with feeding issues, reflux, or oral aversion. Fluoride and occupational oral-motor plans help tolerance of tooth brushing and dental procedures. National Organization for Rare Disorders

19. Safety & fall-prevention planning
    Home and school safety reviews (gates, seating, harnesses as needed, adaptive strollers) reduce injury risk while children are learning new motor skills. Teams advocate for appropriate supports under disability law. National Organization for Rare Disorders

20. Transition planning for adolescence
    As children age, plan for vocational training, life-skills teaching, and health care transition to adult providers familiar with neurodevelopmental disabilities. Early planning eases stress and maintains services. National Organization for Rare Disorders

---

Drug treatments

Important: none of the medicines below is approved to “treat KAT6A syndrome itself.” They are commonly used for specific problems (seizures, spasticity, reflux, constipation, sialorrhea, sleep disturbance, attention) that some children with KAT6A may have. Dosing must be individualized by the child’s clinician.

1. Levetiracetam – for seizures
   Class: antiepileptic. Typical pediatric dosing is weight-based; oral and IV forms exist. Given twice daily (or extended-release once daily in appropriate ages), it reduces a broad range of seizure types. Mechanism involves SV2A modulation. Side effects can include irritability, somnolence, and rarely mood changes; renal adjustment is needed. Evidence and dosing are from FDA labeling. FDA Access Data+2FDA Access Data+2

2. Baclofen – for troublesome spasticity/hypertonia
   Class: skeletal muscle relaxant (GABA_B agonist). Gradual titration reduces muscle stiffness and spasms; abrupt withdrawal can cause serious reactions (seizures, fever, rebound spasticity). Drowsiness and low tone can occur. Multiple oral formulations are FDA-approved. FDA Access Data+2FDA Access Data+2

3. Omeprazole – for reflux symptoms (GERD) when clinically indicated
   Class: proton-pump inhibitor. Reduces gastric acid to help esophagitis and acid-related symptoms under pediatric GERD guidance. FDA labeling details dosing and safety; therapy should be time-limited and monitored. Side effects may include headache, abdominal pain, or (rarely) rash. FDA Access Data+2FDA Access Data+2

4. Polyethylene glycol 3350 (PEG 3350, MiraLAX®) – for constipation
   Class: osmotic laxative. Mixed in liquid daily, it softens stool without cramping, often first-line in pediatrics. Dosing is weight-based; effects appear within 1–3 days. Side effects are usually mild (bloating, loose stools). FDA approval and labeling are available. FDA Access Data+1

5. Bisacodyl – stimulant rescue for constipation
   Class: stimulant laxative. Short courses can “rescue” when PEG alone is insufficient; rectal forms are also used. Labeling warns to avoid chronic overuse; cramps and diarrhea may occur. FDA Access Data+1

6. Glycopyrrolate oral solution (Cuvposa®) – for severe drooling (sialorrhea)
   Class: anticholinergic. Reduces saliva volume and drooling burden, improving skin integrity and social participation; dose titrated by weight. Watch for constipation, urinary retention, flushing, or behavior changes. FDA Access Data+1

7. Metoclopramide – prokinetic for selected reflux/gastroparesis cases
   Class: dopamine antagonist. May speed gastric emptying and increase LES tone; because of tardive dyskinesia risk, use is time-limited and closely monitored. Most children with KAT6A do not need it, but GI specialists may consider it in select situations. FDA Access Data+2FDA Access Data+2

8. Tasimelteon (Hetlioz®/Hetlioz LQ®) – circadian-sleep regulator in specific cases
   Class: melatonin-receptor agonist (MT1/MT2). FDA-approved for non-24-hour sleep-wake disorder (including pediatric labeling for Hetlioz LQ). Pediatric neurologists sometimes consider it when circadian dysregulation is diagnosed. Monitor for next-day sleepiness and interactions. FDA Access Data+1

9. Clonidine ER (Kapvay®) – for ADHD symptoms (if present) or sleep-onset problems
   Class: central alpha-2 agonist. May reduce hyperactivity/impulsivity and support sleep initiation. Slow titration prevents hypotension; taper to avoid rebound hypertension. Pediatric ADHD labeling applies. FDA Access Data+1

10. Palivizumab (Synagis®) – RSV prophylaxis in high-risk infants
    Class: monoclonal antibody. Not KAT6A-specific, but some medically fragile infants (e.g., with significant hypotonia or GI/respiratory complications) may qualify under local criteria to reduce RSV hospitalization risk. Monthly injections during RSV season. FDA Access Data+1

11. Polyethylene glycol-electrolyte solutions (GoLYTELY®, NuLYTELY®) – bowel clean-out
    Class: osmotic lavage solutions used for colon clean-out (e.g., severe fecal impaction) under medical supervision; not for daily use. Pediatric dosing pathways exist in labeling. FDA Access Data+1

12. (Reserved for clinician judgment) Stimulant laxatives (senna) or stool softeners may be used intermittently under pediatric guidance following FDA OTC frameworks; families should avoid chronic unsupervised stimulant use. FDA Access Data

Notes on expectations: Medicines above treat symptoms seen in some children with KAT6A; a given child might only need none, one, or a few of them at any time. Always follow a pediatric specialist’s plan. National Organization for Rare Disorders

---

Dietary molecular supplements

Evidence for supplements specific to KAT6A is limited; use them only when medically indicated (e.g., documented deficiency). Below are common, clinician-guided considerations in neurodevelopmental care; discuss each with your team.

1. Iron – Correcting iron deficiency improves energy, sleep quality, and attention in many children; ferritin-guided dosing prevents overload. GI side-effects include constipation or dark stools; pair with fiber/PEG regimen as needed. (Use only if labs show deficiency.) PMC

2. Vitamin D – Supports bone health and immunity; low levels are common in children with limited outdoor activity or feeding restrictions. Dosing is lab-guided to reach sufficiency, with caution to avoid hypercalcemia. PMC

3. Calcium – Partnered with vitamin D to maintain bone mineralization, particularly in low-mobility children. Use diet first; supplement only to fill gaps to age-appropriate totals. PMC

4. Omega-3 fatty acids (DHA/EPA) – May aid general neurodevelopmental health and reduce constipation hardness in some cases; evidence is mixed and not KAT6A-specific. Watch for fishy aftertaste and bleeding risk at high doses. National Organization for Rare Disorders

5. Probiotics – Selected strains can support stool regularity and reduce antibiotic-associated diarrhea. Choose child-tested products; discontinue if bloating or fussiness worsens. PMC

6. Fiber supplements (inulin/psyllium) – Useful when a child’s texture limits restrict natural fiber. Start low, go slow, and maintain fluids to avoid bloating; combine with PEG if needed. PMC

7. Multivitamin – Consider a simple, age-appropriate formulation to “backfill” otherwise hard-to-reach micronutrients during restricted-texture feeding phases. Avoid megadoses. PMC

8. Zinc – Only if deficiency is proven; supports taste, appetite, and immunity. Excess can cause nausea and copper deficiency. PMC

9. Magnesium – May modestly soften stool and help sleep in some children; excessive doses cause diarrhea. Use pediatric dosing and avoid in renal impairment. PMC

10. Protein modulars – Dietitians sometimes add whey or peptide-based powders to meet growth needs in kids with low volume intake, respecting allergy and GI tolerability. PMC

---

Immunity-booster / regenerative / stem-cell” drugs

There are no FDA-approved “immune-booster,” “regenerative,” or “stem-cell” drugs for KAT6A syndrome. A few FDA-licensed hematopoietic stem cell products exist, but they are indicated for blood/immune disorders—not neurodevelopmental syndromes like KAT6A. Families should avoid unproven stem-cell clinics. Where immune protection is important for fragile children, clinicians focus on evidence-based prevention (e.g., standard vaccinations and, in select infants, RSV monoclonal prophylaxis). FDA Access Data

To align with your request for six entries while staying evidence-based, here are six FDA-regulated options relevant to overall protection, not as KAT6A treatments:

1. Routine childhood immunizations – Strongest “immunity program” for all children; follow your national schedule. (Administered under licensed biologics/approved vaccines.)

2. Palivizumab (Synagis®) – Seasonal RSV prophylaxis for qualifying high-risk infants to lower severe RSV risk.

3. Influenza vaccine (annual) – Reduces flu complications and hospitalization risk; crucial for medically complex children.

4. COVID-19 vaccination (age-eligible) – Reduces severe disease; follow current pediatric guidance.

5. Pneumococcal vaccinations (as scheduled) – Protect against invasive pneumococcal disease; catch-up dosing where indicated.

6. Tasimelteon / sleep optimization – Not an immune drug, but sleep stabilization supports daytime function and caregiver health; included here only as a realistic, regulated strategy improving resilience.

(Among these, only palivizumab comes from the drug labeling cited earlier; vaccines are licensed/authorized products delivered per public-health schedules.) FDA Access Data

---

Surgeries (when and why)

1. Gastrostomy tube (G-tube) placement
   Procedure: Endoscopic or surgical creation of a small abdominal opening to the stomach with a feeding button/tube.
   Why it’s done: For persistent unsafe swallow, inadequate growth, severe oral aversion, or when reflux therapies require reliable medication/nutrition delivery. It can be temporary or long-term, with plans to transition back to full oral feeds if possible. PMC

2. Fundoplication (select cases of severe GERD)
   Procedure: Laparoscopic wrap of the upper stomach around the lower esophagus to reduce reflux.
   Why it’s done: When GERD causes aspiration, recurrent pneumonias, or severe pain despite optimized medical/feeding strategies; chosen by pediatric GI and surgery per guideline pathways. NASPGHAN

3. Strabismus surgery
   Procedure: Adjusts extraocular muscles to align the eyes; often outpatient.
   Why it’s done: To improve alignment, reduce amblyopia risk, and support binocular vision when glasses/patching are insufficient. AAO+1

4. Adenotonsillectomy for obstructive sleep apnea
   Procedure: Removal of adenoids and tonsils.
   Why it’s done: First-line treatment for pediatric OSA when tonsillar/adenoidal hypertrophy contributes to symptoms; improves sleep quality, daytime behavior, and growth. CPAP is used if OSA persists. AAP Publications+1

5. Orthopedic procedures
   Procedure: Soft-tissue lengthening, tendon releases, or bony procedures if contractures/scoliosis develop.
   Why it’s done: To ease caregiving, improve positioning, or enable bracing and mobility when therapy and orthotics aren’t enough. Decisions are individualized by pediatric ortho teams. National Organization for Rare Disorders

---

Prevention priorities

1. Keep vaccinations up to date; ask about RSV prevention if your infant is high-risk. FDA Access Data

2. Use an early-intervention program and attend all therapies; small daily practice adds up. National Organization for Rare Disorders

3. Follow pediatric GERD and constipation plans—diet, routines, and medicines as directed—to prevent pain and hospital visits. PMC

4. Prioritize sleep hygiene; screen for OSA if there is snoring, pauses, or restless sleep. AAP Publications

5. Schedule regular vision and hearing checks to protect language and learning. AAO

6. Build safe mobility: PT home program, orthotics, and fall-prevention in the home/classroom. National Organization for Rare Disorders

7. Prevent dental problems with daily care and fluoride; reflux can raise dental risk. National Organization for Rare Disorders

8. Maintain growth with dietitian guidance; consider PEG early if oral intake is unsafe/inadequate. PMC

9. Coordinate care through a medical home; bring a single medication list and IEP to visits. National Organization for Rare Disorders

10. Connect with KAT6A community groups for practical tips and emotional support. Kat6A

---

When to see doctors urgently

Seek medical care now for choking or color change during feeds, repeated vomiting with lethargy, dehydration, seizures, breathing pauses, new weakness, unrelieved pain, or sudden behavior change. Contact your team promptly for poor weight gain, persistent constipation despite a plan, uncontrolled reflux, snoring with pauses, eye crossing that worsens, or developmental regression. These problems have treatable causes and should not be “waited out.” PMC+1

---

What to eat and what to avoid (simple guide)

Eat more of: balanced meals with protein, fruits/vegetables (soft/mashed as needed), whole-grain fiber, and sufficient fluids. For kids who struggle with textures, dietitians may suggest smoothies, yogurts, purees, or peptide-based formulas to meet nutrition while practicing oral skills. Avoid or limit: reflux triggers individual to your child (acidic, very spicy, or high-fat meals near bedtime), dehydrating sugary drinks that worsen constipation, and hard-to-chew textures until oral-motor skills improve. Follow any allergy restrictions, and never use restrictive “diets” without your team. PMC

---

Frequently asked questions

1) Is there a cure for KAT6A?
No. Care focuses on building skills and treating symptoms like feeding issues, reflux, constipation, sleep problems, eye misalignment, and—when present—seizures. PMC+1

2) Will my child walk and talk?
Many children walk and use words or AAC with time and therapy; timelines vary widely. Early intervention helps maximize potential. PMC

3) Is KAT6A inherited?
Most variants are de novo (new in the child), but the condition is autosomal dominant; a parent with the variant can pass it on. Genetic counseling explains recurrence risk. PMC

4) What medical problems need monitoring?
Feeding/swallow, reflux, constipation, vision/strabismus, hearing, sleep, growth/nutrition, and development. Your team tailors screening and referrals. National Organization for Rare Disorders

5) Are there research studies?
Yes. Cohorts and scoping reviews are expanding, and foundations list ongoing projects. Ask genetics about registries and trials. Kat6A+1

6) Which therapies matter most?
Speech-language therapy with AAC, PT, OT, and feeding therapy are cornerstones; school supports and caregiver training sustain gains. PMC+1

7) Are PPIs safe for reflux?
They’re effective for acid-mediated disease but should be used at the lowest effective dose and time-limited per pediatric GERD guidelines. NASPGHAN

8) How is constipation best managed?
Daily routines plus PEG 3350 are first-line; add rescue agents briefly if needed, guided by your pediatrician. FDA Access Data

9) Should we try stem-cell therapy?
No—there is no FDA-approved stem-cell therapy for KAT6A; avoid unregulated clinics. Stick to evidence-based care and research pathways. National Organization for Rare Disorders

10) What about seizures?
Not all children have seizures; if they occur, neurologists often use levetiracetam among first choices and monitor response and side effects. FDA Access Data

11) Does sleep apnea matter?
Yes. Treating OSA (often adenotonsillectomy, then CPAP if needed) can improve daytime behavior and growth. AAP Publications+1

12) Are drooling and saliva issues treatable?
Yes. Positioning/therapy first; glycopyrrolate oral solution is an option if severe, with side-effects to monitor. FDA Access Data

13) Who coordinates all this?
Ask your pediatrician to serve as a medical home linking therapies, school, GI, neuro, genetics, ophthalmology, ENT, and dentistry. National Organization for Rare Disorders

14) How can we support communication early?
Start AAC immediately—pictures/signs/devices—while continuing speech therapy. AAC supports, not blocks, spoken language. PMC

15) Where can we learn from other families?
KAT6A-focused organizations and rare-disease groups maintain guides, webinars, and research updates. Kat6A

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 02, 2025.